GUARDANT HEALTH, INC.

(GH)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
43.66 USD   +8.23%
06/21GUARDANT HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/14TRANSCRIPT : Guardant Health, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 09:20 AM
CI
06/13Guardant Health Closes Guardant Health AMEA Joint Venture Buyout for $177.8 Million
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
44.41(c) 42.26(c) 42.04(c) 40.34(c) 43.66(c) Last
1 159 693 947 724 1 040 786 1 365 882 833 629 Volume
-3.98% -4.84% -0.52% -4.04% +8.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 466 M - -
Net income 2022 -508 M - -
Net Debt 2022 336 M - -
P/E ratio 2022 -9,05x
Yield 2022 -
Sales 2023 625 M - -
Net income 2023 -481 M - -
Net Debt 2023 547 M - -
P/E ratio 2023 -9,50x
Yield 2023 -
Capitalization 4 450 M 4 450 M -
EV / Sales 2022 10,3x
EV / Sales 2023 8,00x
Nbr of Employees 1 373
Free-Float 95,3%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. It has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need... 
More about the company
Ratings of Guardant Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GUARDANT HEALTH, INC.
06/21GUARDANT HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/14TRANSCRIPT : Guardant Health, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare..
CI
06/13Guardant Health Closes Guardant Health AMEA Joint Venture Buyout for $177.8 Million
MT
06/13GUARDANT HEALTH : Completes Purchase of Guardant Health AMEA Joint Venture - Form 8-K
PU
06/13Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
BU
06/13GUARDANT HEALTH, INC. : Termination of a Material Definitive Agreement, Other Events, Fina..
AQ
06/07TRANSCRIPT : Guardant Health, Inc. Presents at William Blair’s 42nd Annual Growth Sto..
CI
06/03Piper Sandler Starts Guardant Health at Overweight With $65 Price Target
MT
05/26Guardant Health to Participate in Upcoming June Investor Conferences
BU
05/25First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d..
BU
05/25First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational At Vall d..
CI
05/23Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 Ame..
BU
05/21Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal C..
BU
05/21Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colore..
CI
05/10TRANSCRIPT : Guardant Health, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
More news
News in other languages on GUARDANT HEALTH, INC.
06/13Guardant Health conclut le rachat de la coentreprise Guardant Health AMEA pour 177,8 mi..
05/26Erste Dienstleistung von Guardant Health für Flüssigbiopsie-Tests in Europa jetzt in Be..
05/26Le premier service de test de biopsie liquide de Guardant Health en Europe est désormai..
05/25VHIO se sitúa como referente en el uso de biopsia líquida gracias a la incorporación, p..
05/25Le premier service de test de biopsie liquide de Guardant Health en Europe est maintena..
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 43,66 $
Average target price 111,75 $
Spread / Average Target 156%
EPS Revisions
Managers and Directors
Helmy Eltoukhy Chairman & Co-Chief Executive Officer
AmirAli H. Talasaz Co-Chief Executive Officer & Director
Michael Bell Chief Financial & Accounting Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capi. (M$)
GUARDANT HEALTH, INC.-56.35%4 450
EXACT SCIENCES CORPORATION-49.39%6 930
BGI GENOMICS CO., LTD.-19.24%4 387
IOVANCE BIOTHERAPEUTICS, INC.-39.92%1 735
BEIJING STRONG BIOTECHNOLOGIES, INC.-12.36%1 520
SEEGENE, INC.-44.43%1 439